The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B

The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B

Source: 
Endpoints
snippet: 

They may be late, but Lundbeck is now officially in the game for preventing migraine with CGRP drugs.

The FDA has OK’d eptinezumab, the prize in Lundbeck’s $2 billion acquisition of Alder. Like rival offerings from Amgen/Novartis, Eli Lilly and Teva, the antibody blocks the calcitonin gene-related peptide, which is believed to dilate blood vessels in the brain and cause pain.